Veldoreotide: A Novel Somatostatin Analogue for Acromegaly

Veldoreotide, or COR-005, is an investigational somatostatin analogue (SSA) in development for treatment of patients with acromegaly

SSAs bind to somatostatin receptors, inhibiting secretion of growth hormone. This activity is also associated with undesirable inhibition of other endocrine hormones (eg, insulin, glucagon) in locations outside the pituitary.

We believe that veldoreotide may offer an improved safety and efficacy profile—compared with current SSAs—because of its differentiated activation of somatostatin receptor subtypes. Veldoreotide has received orphan drug designation for acromegaly in the US and EU.

Veldoreotide is currently being optimized for sustained release and subcutaneous delivery.

Differential Inhibition of Growth Hormone and Insulin Secretion by veldoreotide Studied

In short-term Phase 1 and 2 studies in healthy volunteers and untreated patients with acromegaly, respectively, the effects of subcutaneously administered veldoreotide on stimulated or basal growth hormone and postprandial glucose and insulin secretion were compared with those of subcutaneous injections of immediate-release octreotide. The findings suggest that veldoreotide has similar ability as octreotide to suppress growth hormone but has reduced propensity to inhibit postprandial insulin.1,2

Findings from these studies suggest that veldoreotide warrants further investigation as a treatment for acromegaly.

No serious adverse events were observed, and mostly mild adverse events typical for SSAs such as injection site reactions and gastrointestinal side effects were reported. There was no evidence that veldoreotide adversely affects the liver, kidneys, or other organ systems, including the cardiovascular system.

The safety and efficacy of veldoreotide for treatment of acromegaly have not been established.


  1. Data from phase 1 single-blind placebo-controlled multiple ascending dose study in 42 healthy male subjects given 300 µg octreotide or COR-005 100-1800 µg tid sc over 6 days.
  2. Data from a phase 2 open-label, single ascending dose study in 20 subjects with acromegaly, fixed-dose sequence with 1 week wash-out between treatments of 300 µg sc octreotide, followed by COR-005 100–1800 µg sc, under fasting conditions.

© 2016 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V7 12/2016

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200